ZENTALIS PHARMACEUTICALS INC's ticker is ZNTL and the CUSIP is 98943L107. A total of 123 filers reported holding ZENTALIS PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is 0.18 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $80,481 | -35.4% | 4,012 | -9.1% | 0.05% | -33.8% |
| Q2 2023 | $124,547 | +43.0% | 4,415 | -12.8% | 0.07% | +54.2% |
| Q1 2023 | $87,118 | -38.3% | 5,065 | -27.7% | 0.05% | -35.1% |
| Q4 2022 | $141,181 | +35.8% | 7,010 | +45.5% | 0.07% | +80.5% |
| Q3 2022 | $104,000 | -22.4% | 4,819 | +0.7% | 0.04% | -18.0% |
| Q2 2022 | $134,000 | +34.0% | 4,786 | +120.7% | 0.05% | +11.1% |
| Q1 2022 | $100,000 | -48.5% | 2,169 | -5.9% | 0.04% | -38.4% |
| Q4 2021 | $194,000 | -23.3% | 2,305 | -39.2% | 0.07% | -34.2% |
| Q3 2021 | $253,000 | +19.3% | 3,794 | -5.0% | 0.11% | +27.6% |
| Q2 2021 | $212,000 | -15.9% | 3,992 | -31.4% | 0.09% | -17.9% |
| Q1 2021 | $252,000 | -15.2% | 5,819 | +1.9% | 0.11% | -13.8% |
| Q4 2020 | $297,000 | – | 5,711 | – | 0.12% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Paradigm Biocapital Advisors LP | 300,434 | $25,254,000 | 7.21% |
| TYBOURNE CAPITAL MANAGEMENT (HK) LTD | 2,628,409 | $220,944,000 | 6.56% |
| Avidity Partners Management LP | 2,715,000 | $228,223,000 | 4.84% |
| Matrix Capital Management Company, LP | 4,349,279 | $365,600,000 | 4.07% |
| Affinity Asset Advisors, LLC | 117,500 | $9,877,000 | 3.59% |
| Integral Health Asset Management, LLC | 120,000 | $10,087,000 | 2.79% |
| Ghost Tree Capital, LLC | 80,000 | $6,725,000 | 2.41% |
| Ikarian Capital, LLC | 191,140 | $16,067,000 | 2.39% |
| Tri Locum Partners LP | 23,632 | $1,987,000 | 0.78% |
| Eventide Asset Management | 529,000 | $44,468,000 | 0.57% |